arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BIOGEN INC.

BIIB
$207.99 ▲ +1.67 (+0.81%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
74 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOGEN INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $30.6B
Dividend Yield
Revenue Growth 1.9%
Op. Margin None
ROIC None
FCF / Share $4.04
Trailing P/E 95.9x
Price / Book
FCF Yield 1.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.48B
↑ +1.9%
Net Income Profit after all expenses
$319.50M
↑ +32.8%
Operating Margin Operating profit as % of sales
24.1%
↓ -15.6%
FCF / Share Free cash flow per share
$4.04
↑ +165.5%
Long-Term Debt Long-term obligations
$6.29B
— 0.0%

Health Breakdown

Profitability
77
Cash Quality
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters